Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease
Details : Vevizye is a clear ciclosporin 0.1% solution, free of oils, surfactants, and preservatives. It is indicated for the treatment of moderate to severe dry eye disease.
Brand Name : Vevizye
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 29, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CyclASol (cyclosporine) solubilized in a novel water-free excipient, perfluorobutylpentane, it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Brand Name : CyclASol
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 24, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through acquisition, Harrow gains U.S. and Canadian commercial rights for Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ophthalmic solution prescription drug based on Novaliq’s proprietary EyeSol® water-free technology.
Brand Name : Vevye
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Harrow
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Senju acquires Japan rights to develop, manufacture, and commercialize NOV03 (perfluorohexyloctane ophthalmic solution), the first and only prescription treatment for signs and symptoms of dry eye disease that directly targets tear e...
Brand Name : NOV'03
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 13, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Vevye (cyclosporine ophthalmic solution) is solubilized in a novel and was designed to address unmet needs, providing patients with a fast acting and well tolerable dry eye drug therapy.
Brand Name : Vevye
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 08, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Approved
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Miebo (perfluorohexyloctane) is the first drug approved by USFDA to treat dry eye disease associated with Meibomian gland dysfunction. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the Meibomian glands.
Brand Name : Miebo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 18, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CyclASol® consists of cyclosporine solubilized in a novel water-free excipient, perfluorobutylpentane , it is specifically developed as a potent and comfortable anti-inflammatory dry eye drug therapy with rapid onset of effect for dry eye patients.
Brand Name : CyclASol
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 08, 2023
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NOV03 (Perfluorohexyloctane) is the first drug developed to treat dry eye disease associated with Meibomian gland dysfunction in a highly effective way. It stabilizes the lipid layer for hours to protect the tear film and has the ability to penetrate the...
Brand Name : 37926
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 04, 2023
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CyclASol® (cyclosporine ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED).
Brand Name : CyclASol
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 24, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : NOV03 (perfluorohexyloctane) A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).
Brand Name : 37926
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2022
Lead Product(s) : Perfluorohexyloctane
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Bausch & Lomb Incorporated
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?